SHIVOM
SHIVOM - THE NEXT ERA OF GENOMICS AND HEALTHCARE
A unique and empowering Project, Shivom will enable DNA data donors to collaborate with revolutionary changemakers in biotechnology, healthcare industry, and government-ordained research institutes and contribute to an unprecedented era of medical marvels.
The world of healthcare is changing. Two revolutionary technologies, genomics, and blockchain, are poised to significantly improve health and well-being across the globe. Genomic medicine can enhance the understanding and treatment of as many as 7,000 rare diseases, alongside cancers, complex and long-term disease such as cardiovascular and neurodegenerative conditions, and infections.
Shivom offers the first ever integrated solution for patients and genome data donors where everybody will be able to have their genome sequenced and securely stored. This ecosystem will provide an open web-marketplace for other providers such as pharmaceuticals, research organizations, governments, patient-support groups and insurance companies to add their apps and services, alongside genomic data analytics and personalized medicine
WHY SHOULD YOU CHOOSE SHIVOM
To make the direct-to-consumer business more open, fair, and beneficial to all users, the Shivom platform uses blockchain technology to create a disruptive genomics ecosystem. It ensures data is owned by the data donors themselves. It ensures a transparent and secure bridge to organizations interested in using that data.
- Genome data donors own their data and access rights
- Donors gain rewards for sharing their genomic data on the blockchain by selling access rights directly to third party institutions such as pharmaceutical companies
- Pharmaceutical companies use the Shivom platform to refine drug development
- Shivom users have full and fine-grained control of who can access the data even after a third party institution has had access to it
- Patients get personalized health, well-being, and lifestyle information
- A dynamic ecosystem is created and continuously refined in which the community can identify and remove potential health roadblocks before they become serious
OUR VISION
Accelerate the age of genomics
Every one of the 7.6 billion people on earth has a unique code held within their genes that unlocks the secrets to appearance, ancestry, intellectual capabilities, health, and fitness. But, this code’s ability to reveal predisposition to disease has been overlooked.
Improve global health
Now is the time for concerted, community-wide development for the “genomical” challenges of the coming decade. Currently, a few key players hold the monopoly on genomic data and make huge profits from selling it to 3rd parties, usually without sharing the earnings with the data donor.
Jumpstart genome-based precision medicine
We are changing the dynamics of the global healthcare market. We are utilizing the most advanced technologies including blockchain, cloud computing, genome sequencing, artificial intelligence, and big data analytics to bring medical genomics into a new era.
Accelerate the age of genomics
Every one of the 7.6 billion people on earth has a unique code held within their genes that unlocks the secrets to appearance, ancestry, intellectual capabilities, health, and fitness. But, this code’s ability to reveal predisposition to disease has been overlooked.
Ensure the next level of data privacy
We are at the forefront of data security. We use state-of-the-art cryptography to add additional security levels to our platform that go well beyond blockchain technology for decentralization, protecting each user’s data from cybercriminal
THE BENEFITS GIVEN BY GENOMIC SEQUENCING
- Identifying the best course of care for patients with a particular condition
- Prevention of disease in healthy individuals
- Prediction of disease risk
- Disease diagnosis
- Treatment, including choice of most effective medication and dosage
- Disease prognosis
- Identifying new drug targets
TOKEN SALE
The level of funding received dictates the distribution of funds.
However, reserve structure allows us to reduce the volatility along
the way while achieving long-term objectives.
20% Platform Development
Database building, UI, APIs, and metadata curating. A large part of this budget will be used to make the platform secure and scalable. From there we will implement new features and create the open marketplace.
11% Operations & Business Development
Day-to-day operations, team building (developers, geneticists, marketers and product managers). Forming the Foundation.
10% Non-Profit R&D Platform
Drug discovery platform combining elements of Big Data analytics, artificial intelligence, genomics, proteomics, lipidomics, and metabolomics.
21% Marketing & Forming Partnerships
Ongoing community-building events public communications via traditional marketing channels and persona-based approaches. This also includes educational materials, roadshows, collaboration with other genomics-initiatives, organizing events and conferences, and KOL management.
5% Legal
Regulatory compliance for all markets Shivom operates in.
2% Initial PoC
First sequencing project in hospitals in rural India.
6% Data Storage
Forecasted to sustain the platform during the first few years.
25% Laboratories
Setting up a global network of laboratories and counseling services.
ROADMAP
➤ Dec 2016
conceptualization healthcare ecosystem initiated
➤ Aug 2017
seed round of $250k finished
➤ Oct 2017
start of global roadshow
➤ Mar 2018
whitepaper released
➤ April 2018
OmiX token sale starts
➤ Q1-Q2 2018
Shivom foundation established (Foundation director and first steering committee members on board)
➤ Q1 2018
partnership major crypto vc
➤ Apr 2018
project gaia started (Sequencing project in rural India commenced)
➤ Apr 2018
partnership medical center.(Collaboration with first of many large clinical centers)
➤ Q2 2018
partnership major data analytics firm (Co-development to connect Shivom platform with stat-of-the art data analytics pipeline)
➤ Q2 2018
pharma partner on board (Collaboration with Top 25 pharmaceutical company)
➤ Apr 2018
platform alpha release
➤ Q2/Q3 2018
web marketplace open
➤ Q3/Q4 2018
formation R&D unit (Official start of global not-forprofit pharmaceutical spin-of)
➤ Q4 2018
first genomics service unit opens (First genomics counseling service unit opens)
➤ Q4 2018
first rare- disease subset (Set of large group of people sequenced with rare disease)
➤ Q3/Q4 2018
worldwide rollout of Shivom platform (Shivom services are available on a global scale on all continents)
➤ Q4 2018/Q1 2019
multi-omics integration
➤ Q4 2018/Q1 2019
A.I. platform (Implementation of artificial intelligence, deep learning platform).
MORE FOR INFORMATION PLEASE VISIT :
Author : Satria99
My Profile : https://bitcointalk.org/index.php?action=profile;u=1940293;sa=forumProfile
ETH : 0x95263fDb033E049Fb739fF09a7f08C4e6D934081
Komentar
Posting Komentar